SAB Biotherapeutics (SABS) Debt Ratio (2020 - 2022)

SAB Biotherapeutics (SABS) reported Debt Ratio of 0.01 for Q4 2022, up 249.68% quarter-over-quarter from 0.0 in Q4 2020.

SAB Biotherapeutics (SABS) Debt Ratio (2020 - 2022) Analysis & Trends

SAB Biotherapeutics has reported Debt Ratio for 2 years, with the latest figure at 0.01 in Q4 2022.

For the quarter ending Q4 2022, Debt Ratio changed N/A year-over-year to 0.01; the trailing twelve-month figure through Dec 2022 stood at 0.01 (changed N/A YoY), and the FY2022 full-year result was 0.01, changed N/A from the prior year.
Debt Ratio for Q4 2022 stood at 0.01, up from 0.0 in the prior quarter.
The five-year high for Debt Ratio was 0.01 in Q4 2022, with the low at 0.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.18
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	SAB Biotherapeutics	214.77 Mn	214.77 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	0.01
Dec 31, 2020	0.00